Indaptus Therapeutics financials
$2.85−13.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M |
| Net income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.7M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-21.58 | $-44.96 | $-51.24 | $-48.44 | $-52.92 |
| EBITDA | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M |
| Operating cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Free cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Diluted shares | 1.0M | 0.3M | 0.3M | 0.3M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $8.5M | $5.8M | $13.4M | $9.6M | $39.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $16.8M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M |
| Total liabilities | $6.2M | $3.4M | $2.8M | $3.4M | $4.7M |
| Shareholders' equity | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology